(Q42164176)

17 October 2017

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial (English)

1 reference

17 October 2017

1 reference

1 reference

3

Eugene Braunwald

1 reference

17 October 2017

12

Elliott M Antman

1 reference

17 October 2017

11

Carolyn H McCabe

1 reference

17 October 2017

9

Sabina A Murphy

1 reference

17 October 2017

13

Stephen D Wiviott

1 reference

TRITON-TIMI 38 Investigators

17 October 2017

14

object named as

TRITON-TIMI 38 Investigators

1 reference

17 October 2017

1

Alan D Michelson

1 reference

17 October 2017

2

Andrew L Frelinger

1 reference

17 October 2017

7

Joseph A Jakubowski

1 reference

17 October 2017

5

Dominick J Angiolillo

1 reference

17 October 2017

William E Downey

4

1 reference

17 October 2017

Nicholas P Xenopoulos

6

1 reference

17 October 2017

Youfu Li

8

1 reference

17 October 2017

Jie Qin

10

1 reference

17 October 2017

12 May 2009

1 reference

17 October 2017

European Heart Journal

1 reference

17 October 2017

30

1 reference

17 October 2017

14

1 reference

17 October 2017

1753-1763

1 reference

Platelets in atherothrombosis

17 October 2017

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

P2Y12 antagonism: promises and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Clopidogrel response variability, resistance, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Clopidogrel linking evaluation of platelet response variability to mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

Measuring antiplatelet drug effects in the laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHP159

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHP159

1 reference

17 October 2017

1 reference